Diabetes Resources
|
The OmniPod Insulin Management System provides Continuous Subcutaneous Insulin Infusion (CSII) therapy, an intensive insulin therapy for diabetes that is often called insulin pump therapy. CSII therapy mimics the action of a healthy, insulin-producing pancreas, which releases precise amounts of rapid-acting insulin in response to the body’s need for insulin around the clock. In CSII therapy, you use a medical device such as the OmniPod System to deliver precise amounts of rapid-acting insulin through a small, flexible tube (cannula) that you insert every few days into the tissue underneath the skin (subcutaneous tissue). The device provides two types of insulin delivery to help you manage your body’s need for insulin:
Your healthcare provider can help you to figure out your basal and bolus insulin needs. And, as with any therapy for diabetes, you'll need to check your blood glucose on a regular basis to make sure you're staying on target. |
![]()
|
Compared to insulin injections, CSII therapy offers better blood glucose control, more stable blood glucose, lower doses of insulin [1] and fewer blood glucose ‘lows’ (hypoglycemia) [2].
And, intensive insulin therapies such as CSII therapy have been proven to reduce common long term complications of diabetes, including eye, nerve, kidney, and heart disease, by up to 76% [3].
What’s more, with CSII there are no painful insulin injections, insulin dosing is very precise, and you don’t have to try to fit your life around your insulin doses. You simply adjust your insulin delivery to fit whatever you’re doing, whenever you do it. So you can eat, exercise and sleep as you please.
The bottom line: with the control that CSII therapy provides, you’ll live the way you choose, feel better on a daily basis and be taking better care of yourself for the long term.
Very few people that go on CSII therapy ever look back. And, with the OmniPod Insulin Management System, you’ll get all the benefits of CSII therapy in a way that no conventional insulin pump can deliver.
[1] Compared to insulin injections. Hanaire-Broutin H, Melki V, Bessieres-LaCombe S,
Tauber JP. The Study Group for the Development of Pump Therapy in Diabetes. Comparison of continuous
subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1
diabetic patients on intensified treatment. Diabetes Care 2000; 23:1232-1235.
Weissberg-Benchell
J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26:1079-1087.
[2] Reynolds LR. Reemergence of insulin pump therapy in the 1990s. South Med J.
2000; 93:1157-1161.
Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion.
A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents
with type 1 diabetes. Diabetes Care 1999; 22:1779-1784.
Bode BW, Steed RD, Davidson PC. Reduction in
severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes
Care 1996; 19:324-327.
[3] Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993: 329:977-986








